Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. Sudalagunta PR, et al. Among authors: cubitt cl. Cancer Res. 2024 Oct 30. doi: 10.1158/0008-5472.CAN-24-0886. Online ahead of print. Cancer Res. 2024. PMID: 39476082
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma.
Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt C, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby R, Gillies R, Sontag E, Meads MB, Shain KH. Silva A, et al. Cancer Res. 2017 Jun 15;77(12):3336-3351. doi: 10.1158/0008-5472.CAN-17-0502. Epub 2017 Apr 11. Cancer Res. 2017. PMID: 28400475 Free PMC article.
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Xiang Y, et al. Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. doi: 10.1074/mcp.M110.005520. Epub 2011 Aug 16. Mol Cell Proteomics. 2011. PMID: 21846842 Free PMC article.
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Sweet K, et al. Among authors: cubitt cl. Clin Cancer Res. 2020 Jan 1;26(1):54-60. doi: 10.1158/1078-0432.CCR-19-2169. Epub 2019 Oct 21. Clin Cancer Res. 2020. PMID: 31636097 Free PMC article. Clinical Trial.
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. Lancet JE, et al. Clin Cancer Res. 2011 Mar 1;17(5):1140-6. doi: 10.1158/1078-0432.CCR-10-1878. Epub 2011 Jan 13. Clin Cancer Res. 2011. PMID: 21233404 Free PMC article. Clinical Trial.
45 results